
**Supplementary Data**

**Figure 1**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the gender (Blue line: Male patients; Green line: Female patients). P = 0.282.

**Figure 2**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the age (Blue line<40; Green line: 40-59; Yellow line ≥ 60). P < 0.001.

**Figure 3**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the race (Blue line: White patients; Green line: Black or Mulatto patients; Yellow line: others). P < 0.001.

**Figure 4**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the American Society of Anesthesiology classification (ASA) (Blue line: ASA 1 - 2; Green line: ASA 3 - 4). P < 0.001.

**Figure 5**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the Eastern Cooperative Oncology Group (ECOG) performance scale (Blue line: ECOG 0-1; Green line: ECOG ≥ 2). P < 0.001.

**Figure 6**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the Karnofsky performance scale (Blue line: KPS ≤ 80; Green line: KPS > 80). P < 0.001.

**Figure 7**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the presence of anemia (Hb < 10g/dL) (Blue line: No; Green line: Yes). P < 0.001.

**Figure 8**


****

Overall Survival

Follow up (months)

Univariate analysis of overall survival according to the presence of symptons at diagnosis (Blue line: Assymptomatic; Green line: Symptomatic). P < 0.001.

**Figure 8**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the smoking status (Blue line: No; Green line: Former smoker; Yellow line: Smoker). P = 0.454.

**Figure 9**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the tumor size (Blue line: ≤ 4cm; Green line: 4.1 – 7cm; Yellow line: > 7cm). P < 0.001.

**Figure 10**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the pathological tumoral stage (pT) (Blue line: pT1 – pT2; Green line: pT3 – pT4). P < 0.001.

**Figure 11**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the pathological node stage (pN) (Blue line: pN0 and pNx; Green line: pN1). P < 0.001.

**Figure 12**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the peri-renal fat invasion (Blue line: No; Green line: Yes). P < 0.001.

**Figure 13**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the presence of renal vein invasion (Blue line: No; Green line: Yes). P < 0.001.

**Figure 14**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the presence of inferior vena cava invasion (Blue line: No; Green line: Yes). P < 0.001.

**Figure 15**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the Fuhrman grade (Blue line: Grade 1 - 2; Green line: Grade 3 - 4). P < 0.001.

**Figure 16**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the presence of tumoral necrosis(Blue line: No; Green line: Yes). P < 0.001.

**Figure 17**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the presence of microvascular invasion(Blue line: No; Green line: Yes). P < 0.001.

**Figure 18**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the presence of sarcomatoid component (Blue line: No; Green line: Yes). P < 0.001.

**Figure 19**



Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the presence of renal pelvis invasion (Blue line: No; Green line: Yes). P < 0.001.

**Figure 20**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the presence of adrenal gland infiltration (Blue line: No; Green line: Yes). P < 0.001.

**Figure 21**


****

Follow up (months)

Overall Survival

Univariate analysis of overall survival according to the surgical margins status (Blue line: Negative; Green line: Positive). P < 0.001.

**Figure 22**


****

Follow up (months)

Cancer Specific Survival

Univariate analysis of cancer-specific survival according to the gender (Blue line: Male patients; Green line: Female patients). P = 0.351.

**Figure 23**


****

Cancer Specific Survival

Follow up (months)

Univariate analysis of cancer-specific survival according to the age (Blue line <40 years-old; Green line: 40 – 59 years-old; Yellow line ≥ 60 years-old). P = 0.067.

**Figure 24**


****

Follow up (months)

Cancer Specific Survival

Univariate analysis of cancer-specific survival according to the race (Blue line: White; Green line: Black/Mulatto; Yellow line: Others). P < 0.001.

**Figure 25**


****

Follow up (months)

Cancer Specific Survival

Univariate analysis of cancer-specific survival according to the American Society of Anesthesiologists classification (ASA) (Blue line: ASA 1-2; Green line: ASA 3-4). P < 0.001.

**Figure 26**


****

Cancer Specific Survival

Follow up (months)

Univariate analysis of cancer-specific survival according to the Eastern Cooperative Oncology Group (ECOG) performance scale (Blue line: ECOG 0-1; Green line: ECOG ≥2). P < 0.001.

**Figure 27**


****

Cancer Specific Survival

Follow up (months)

Univariate analysis of cancer-specific survival according to the Karnofsky performance scale (Blue line: Karnofsky ≤80; Green line: Karnofsky >80). P < 0.001.

**Figure 28**


****

Follow up (months)

Cancer Specific Survival

Univariate analysis of cancer-specific survival according to the presence of anemia (Hemoglobin <10g/dL (Blue line: No; Green line: Yes). P < 0.001.

**Figure 29**


****

Follow up (months)

Cancer Specific Survival

Univariate analysis of cancer-specific survival according to the presence of symptons at diagnosis (Blue line: Assymptomatic; Green line: Symptomatic). P < 0.001.

**Figure 30**


****

Follow up (months)

Cancer Specific Survival Survival

Univariate analysis of cancer-specific survival according to the smoking status (Blue line: No; Green line: Former smoker; Yellow line: Smoker). P = 0.129.

**Figure 31**


****

Cancer Specific Survival

Follow up (months)

Univariate analysis of cancer-specific survival according to the tumor size (Blue line: ≤4cm; Green line: 4.1 – 7cm; Yellow line: >7cm). P < 0.001.

**Figure 32**


****

Follow up (months)

Cancer Specific Survival Survival

Univariate analysis of cancer-specific survival according the pathogical tumoral stage (pT) (Blue line: pT1 – pT2; Green line: pT3 – pT4). P < 0.001.

**Figure 33**


****

Follow up (months)

Cancer Specific Survival

Univariate analysis of cancer-specific survival according to the pathogical node stage (pN) (Blue line: pN0 and pNx; Green line: pN1). P < 0.001.

**Figure 34**


****

Cancer Specific Survival

Follow up (months)

Univariate analysis of cancer-specific survival according to the presence of perirenal fat invasion (Blue line: No; Green line: Yes). P < 0.001.

**Figure 35**


****

Follow up (months)

Cancer Specific Survival Survival

Univariate analysis of cancer-specific survival according to the presence of renal vein invasion (Blue line: No; Green line: Yes). P < 0.001.

**Figure 36**


****

Cancer Specific Survival

Follow up (months)

Univariate analysis of cancer-specific survival according to the presence of inferior vena cava invasion (Blue line: No; Green line: Yes). P < 0.001.

**Figure 37**


****

Cancer Specific Survival

Follow up (months)

Univariate analysis of cancer-specific survival according to the Fuhrman grade (Blue line: Grade 1-2; Green line: Grade 3-4). P < 0.001.

**Figure 38**


****

Follow up (months)

Cancer Specific Survival

Univariate analysis of cancer-specific survival according to the presence of tumoral necrosis (Blue line: No; Green line: Yes). P < 0.001.

**Figure 39**


****

Cancer Specific Survival

Follow up (months)

Univariate analysis of cancer-specific survival according to the presence of microvascular invasion (Blue line: No; Green line: Yes). P < 0.001.

**Figure 40**


****

Follow up (months)

Cancer Specific Survival

Univariate analysis of cancer-specific survival according to the presence of sarcomatoid component (Blue line: No; Green line: Yes). P < 0.001.

**Figure 41**


****

Cancer Specific Survival

Follow up (months)

Univariate analysis of cancer-specific survival according to the presence of renal pelvis invasion (Blue line: No; Green line: Yes). P < 0.001.

**Figure 42**


****

Follow up (months)

Cancer Specific Survival

Univariate analysis of cancer-specific survival according to the presence of adrenal infiltration (Blue line: No; Green line: Yes). P < 0.001.

**Figure 43**

****

Cancer Specific Survival

Follow up (months)

Univariate analysis of cancer-specific survival according to the surgical margins status (Blue line: Negative; Green line: Positive). P < 0.001.